IFNA1 and coronary artery disorder: The ability of IFN to limit not only HDV infection events, but also to lower intrahepatic viral loads even in resting hepatocytes, would provide a rationale for the stronger anti-HDV effects determined in people with CHD receiving pegIFNα and the entry inhibitor bulevirtide in combination (MYR-203 clinical trial, NCT02637999).44